Price
CHART BY
Frequently asked questions
What is Idorsia's market capitalization?
The market capitalization of Idorsia is CHF 879.20M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Idorsia?
Idorsia's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.536. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Idorsia's stock?
Currently, 4 analysts cover Idorsia's stock, with a consensus target price of CHF 4.433. Analyst ratings provide insights into the stock's expected performance.
What is Idorsia's revenue over the trailing twelve months?
Over the trailing twelve months, Idorsia reported a revenue of CHF 220.61M.
What is the free float of Idorsia's shares?
The free float of Idorsia is 175.18M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- CHF 879.20M
- EPS (TTM)
- -$0.536
- Free Float
- 175.18M
- Revenue (TTM)
- CHF 220.61M
Pricing
- 1D span
- $4.49$4.83
- 52W span
- $1.255$6.058
Analyst Ratings
The price target is CHF 4.433 and the stock is covered by 4 analysts.
Buy
1
Hold
3
Sell
0
Information
Idorsia Ltd. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of medicines for medical needs. It operates through the following geographical segments: Switzerland, United States, Japan, and EUCAN. The company was founded on March 3, 2017 and is headquartered in Allschwil, Switzerland.
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- CH0363463438
- Primary Ticker
- IDIA
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet